Plant Name: Senna tora
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.820E-08 | 7.519E-04 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 6.906E-08 | 7.519E-04 | CDC25B, CSNK2A1, ELANE, ESR1, HIF1A, HPGD, MAPK1, PIM1, THPO, TSHR |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 1.600E-07 | 1.162E-03 | BLM, RECQL, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.181E-07 | 1.821E-03 | CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.608E-06 | 5.003E-03 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.188E-06 | 5.956E-03 | BLM, CSNK2A1, ESR1, ESR2, HPGD, MAPK1, MAPT, NFKB1, SMN1, SMN2, TP53 |
| MF | GO:0005488; binding | GO:1901363; heterocyclic compound binding | 5.660E-06 | 9.480E-03 | BLM, CSNK2A1, CYP2C19, CYP2C9, CYP3A4, ESR1, ESR2, HIF1A, HPGD, HSD17B10, MAPK1, MAPT, NFKB1, PIM1, RECQL, SMN1, SMN2, TDP1, TP53 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 9.266E-06 | 9.989E-03 | CSNK2A1, HIF1A, MAPT |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 9.634E-06 | 9.989E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 9.634E-06 | 9.989E-03 | CYP2C9, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.414E-08 | 6.092E-06 | CYP2C9; ALOX15; CYP3A4; CYP2C19 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.844E-06 | 1.273E-04 | MAPK1; ESR1; NFKB1; ESR2 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.397E-05 | 3.856E-04 | MAPK1; MAPT; TP53; NFKB1; CDC25B |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.077E-05 | 3.856E-04 | CYP2C9; ALOX15; MAPK1; CYP2C19 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.323E-05 | 3.856E-04 | MAPK1; TP53; ESR1; HIF1A |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.595E-05 | 5.731E-04 | LMNA; MAPK1; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.907E-05 | 5.731E-04 | PIM1; MAPK1; TP53; NFKB1; CDC25B |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 4.828E-05 | 8.329E-04 | PIM1; MAPK1; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 6.215E-05 | 9.016E-04 | CYP2C9; ALOX15; CYP2C19 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 7.495E-05 | 9.016E-04 | MAPK1; TP53; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.103E-04 | 1.015E-03 | MAPK1; TP53; HIF1A; ESR1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 6.924E-05 | 9.016E-04 | HPGD; TP53; ELANE; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 7.840E-05 | 9.016E-04 | MAPK1; TP53; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.013E-04 | 9.984E-04 | MAPK1; TP53; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 8.560E-05 | 9.087E-04 | CYP2C9; CYP3A4; CYP2C19 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.825E-04 | 1.482E-03 | MAPK1; TP53; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.652E-04 | 1.926E-03 | PIM1; MAPK1; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.500E-04 | 1.917E-03 | MAPK1; ESR1; ESR2 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.431E-04 | 1.235E-03 | CYP2C9; CYP3A4; CYP2C19 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.810E-04 | 1.939E-03 | MAPK1; HIF1A; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.400E-04 | 2.760E-03 | MAPK1; TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 4.400E-04 | 2.760E-03 | MAPK1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.941E-04 | 3.430E-03 | MAPK1; TP53; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 7.791E-04 | 4.135E-03 | MAPK1; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 6.339E-04 | 3.499E-03 | CSNK2A1; TP53; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.390E-03 | 6.615E-03 | MAPK1; HIF1A; TP53; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.169E-03 | 5.884E-03 | MAPK1; MAPT; HSD17B10 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.899E-03 | 8.256E-03 | MAPK1; NFKB1; TSHR |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.982E-03 | 8.287E-03 | CSNK2A1; TP53; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.067E-03 | 8.389E-03 | MAPK1; TP53; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.542E-03 | 7.092E-03 | CSNK2A1; TP53; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.914E-03 | 8.256E-03 | MAPK1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.217E-03 | 8.739E-03 | MAPK1; TP53 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.973E-03 | 1.001E-02 | MAPK1; TP53 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.540E-03 | 9.473E-03 | MAPK1; HIF1A |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.194E-03 | 5.884E-03 | MAPK1; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 5.966E-04 | 3.430E-03 | MAPK1; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.709E-03 | 9.839E-03 | MAPK1; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 3.734E-03 | 1.120E-02 | MAPK1; NFKB1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 3.536E-03 | 1.120E-02 | MAPK1; TP53 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 8.557E-03 | 2.001E-02 | MAPK1; TP53; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 3.064E-03 | 1.007E-02 | MAPK1; HIF1A |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.295E-03 | 8.799E-03 | MAPK1; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 6.625E-03 | 1.725E-02 | MAPK1; CDC25B |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.973E-03 | 1.001E-02 | CYP2C9; CYP3A4 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 6.111E-03 | 1.622E-02 | TP53; NFKB1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 7.023E-03 | 1.795E-02 | MAPK1; HIF1A |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 3.734E-03 | 1.120E-02 | MAPK1; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 5.141E-03 | 1.419E-02 | TP53; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.734E-03 | 1.120E-02 | CYP2C9; CYP3A4 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 7.710E-03 | 1.867E-02 | MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 8.280E-03 | 1.970E-02 | MAPK1; NFKB1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.834E-03 | 1.126E-02 | CSNK2A1; MAPK1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 7.432E-03 | 1.831E-02 | MAPK1; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 5.986E-03 | 1.620E-02 | CSNK2A1; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 7.432E-03 | 1.831E-02 | MAPK1; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 2.973E-03 | 1.001E-02 | MAPK1; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.702E-02 | 3.613E-02 | CYP2C9; ALOX15; CYP2C19; CYP3A4; HSD17B10 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 5.141E-03 | 1.419E-02 | MAPK1; NFKB1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.652E-02 | 3.561E-02 | THPO; PIM1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 9.476E-03 | 2.180E-02 | MAPK1; NFKB1 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.349E-02 | 2.956E-02 | CSNK2A1; TP53 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.174E-02 | 2.614E-02 | MAPK1; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.936E-03 | 1.132E-02 | MAPK1; NFKB1 |
| hsa03013 | RNA transport_Homo sapiens_hsa03013 | 1.938E-02 | 4.051E-02 | SMN2; SMN1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.001E-02 | 4.122E-02 | MAPK1; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.042E-02 | 2.358E-02 | TP53; CDC25B |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 2.066E-02 | 4.193E-02 | MAPK1; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 2.265E-02 | 4.531E-02 | MAPK1; NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| J00-J99: Diseases of the respiratory system | Pulmonary disease | J00-J99 | ELANE |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ELANE |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ELANE |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; MAPK1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | ELANE |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | ELANE |
| NA: NA | Myocardial ischaemia-reperfusion injury | NA | ELANE |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | ELANE; ELANE; ELANE |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| J00-J99: Diseases of the respiratory system | Pulmonary emphysema | J43 | ELANE |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | ELANE; ELANE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| J00-J99: Diseases of the respiratory system | Mucolytic | J00-J99 | ELANE |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| NA: NA | Acute respiratory distress syndrome | NA | ELANE; ELANE; ELANE |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ELANE |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ELANE; ELANE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| J00-J99: Diseases of the respiratory system | Bronchiectasis | J47, Q33.4 | ELANE |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; MAPK1; NFKB1; ESR1; ESR1; PIM1; CDC25B; CSNK2A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |